{
    "symbol": "AZN",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-10 14:44:10",
    "content": " For Lynparza, we continue to solidify the brand as the leader in the global PARP inhibitor class, product sales grew 19% in the quarter and year-to-date led by growth and adjuvant breast cancer following this year's approvals in the U.S., Europe and Japan with continued global growth in HRD positive ovarian cancer and second-line castration resistant prostate cancer. One financial, one pipeline. So, Andrew, from our perspective, as we continue to look at the performance of Calquence, we see that really the results, whether it's from our own ELEVATE-TN studies, the ALPINE  results, what we're seeing coming out at ASH, that all of this underscores our belief and I think it's consistent with what we hear from the marketplace that the next generation BTKi like Calquence have a differentiated and better profile than the first generation BTKi. One financial, one pipeline. Aradhana, do you want to take the first one? Aradhana, do you want to take the first one?"
}